Red Tree Venture — Full Portfolio

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies that combine tumor-targeting with immune-modulating payloads to treat solid tumors.

IHIvan Hyep(Chief Financial Officer and Treasurer)inLara Meisner(Chief Legal Officer, Compliance Officer and Corporate Secretary)inDRDavid Raben(Chief Medical Officer)in

Co-investorsAIAisling CapitalEIEight Roads VenturesF-F-Prime CapitalFOForesite CapitalPRPremji InvestRARA Capital+6 more

Ceribell is a medical technology company that develops products for detecting and monitoring seizures, including EEG-based diagnostic systems.

AI & Machine LearningDigital HealthHealthtechMedical DevicesSunnyvale, US

JPJosef Parvizi(Director)inX(Xingjuan (Jane) Chao(President, CEO, Co-Founder & Director)inSBScott Blumberg(Executive Officer)inJoseph Taylor(Director)Raymond Woo(Executive Officer)David Stoffel(Executive Officer)

Co-investorsLOLongitude CapitalRARA CapitalSHShangBay Capital LLCTHThe Rise Fund

Contineum is a biopharmaceutical company developing small molecule drug candidates to treat inflammatory and fibrotic diseases by modulating critical disease pathways.

BiotechHealthtech

CSCarmine Stengone(President and Chief Executive Officer)inPTPeter T. Slover(Chief Financial Officer)inDSDaniel S. Lorrain(Chief Scientific Officer)inTimothy R. Watkins(Chief Medical Officer and Head of Development)in

Co-investorsHAHadean VenturesSASamsara BioCapitalCACasdin CapitalFRFranklin TempletonJJJJDCSESectoral Asset Management+1 more

BiotechSan Francisco, US

Donald Manning(Executive Officer)Scott Harris(Executive Officer)Julien Mamet(Executive Officer, Director)Rick Orr(Executive Officer, Director)

BoardDPDennis Podlesak(Director)inEckard Weber(Director)

Board seatHLHeath Lukatch· per SEC Form D · $16M raise · filed Jan 2017

Co-investorsDODomain Associates

Launched by Samsara in partnership with CAR T pioneers, advancing a clinically validated CD22 CAR T for lymphoma.

BiotechSan Mateo, US

GCGina Chapman(Executive Officer, Director)inAnup Radhakrishnan(Executive Officer)inCassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)

BoardAbraham Bassan(Director)

Board seatHLHeath Lukatch· per SEC Form D

Co-investorsNENextech InvestSASamsara BioCapitalWEWellington ManagementALAlly Bridge GroupJAJanus Henderson InvestorsPEPerceptive Xontogeny Venture+1 more

Company whose formation and launch the LifeSci team supported.

BiotechHealthtechSummit, US

Gregory Mayes(Executive Officer, Director, Promoter)Jouko Isojarvi(Executive Officer)Stephen D. Collins(Director)WLWarren Lammert(Director)inOrrin Devinsky(Director)

BoardGBGerry Brunk(Director)in

Board seatHLHeath Lukatch· per SEC Form D · $12M raise · filed Oct 2019

Co-investorsLILifeSci Venture PartnersLULumira Ventures

Acquired.

Digital HealthHardwareWellness & FitnessSan Francisco, US

DCDaniel Chao, M.D., M.S.(Executive Officer, Director)Daniel Chao(Executive Officer, Director)

BoardAFAndrew Firlik(Director)inPHPeter Hebert(Director)inAmol Sarva(Director)

Board seatHLHeath Lukatch· per SEC Form D · $19.8M raise · filed May 2018

Co-investorsJAJAZZ Venture PartnersKDKDDI Open Innovation FundLULux CapitalSTStartXTPTPGXFXfund

Magnus Medical develops SAINT, an FDA-cleared, accelerated form of TMS (transcranial magnetic stimulation) therapy that uses precision neuromodulation to treat Major Depressive Disorder, including treatment-resistant depression, over a 5-day course.

BiotechDigital HealthMedical DevicesMental HealthBurlingame, US

Nolan Williams(Director)Christian Gormsen(Executive Officer, Director)inVLVikram Lamba(Executive Officer)in

BoardXingjuan Chao(Director)inAFAndrew Firlik(Director)in

Board seatHLHeath Lukatch· per SEC Form D · $77M raise · filed May 2026

Co-investorsDODolby Family VenturesJAJAZZ Venture Partners

Satsuma Pharmaceuticals develops therapeutics for the acute treatment of migraine, including an approved dihydroergotamine nasal powder product (Atzumi/STS101).

BiotechHealthtechMedical DevicesSouth San Francisco, US

JKJohn Kollins(Executive Officer, Director)Tadayoshi Iwashima(Executive Officer)TBThomas B. King(President and Board Director)inRJRob Janosky(Chief Commercial Officer)TOTom O'Neil(Chief Financial Officer)inDavid Prichard(Chief Operating Officer)

Board seatHLHeath Lukatch· per SEC Form D · $12.3M raise · filed Feb 2018

Co-investorsOUOUP (Osage University Partners)VIVivo CapitalWEWellington ManagementLULumira VenturesRARA CapitalSBSBI Investment

Transforming the lives of patients through a functional cure for Type 1 Diabetes

BiotechSan Diego, US

Brittany Bradrick(Executive Officer)Anne Sandan(Executive Officer)Elizabeth Bui(Executive Officer)Steve White(Executive Officer)HFHoward Foyt(Executive Officer)inKevin D'Amour(Executive Officer)in

Board seatHLHeath Lukatch· per SEC Form D · $90M raise · filed Dec 2018

Co-investorsARArtis VenturesATATEL VenturesBABain Capital Life SciencesRARA CapitalSASanderling VenturesTHThe Vertical Group+1 more

CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment.

BiotechDeep TechHealthtechMunich, DE

Jörg Wischhusen(Scientific Co-founder)SCScott Clarke(Chief Executive Officer)inPGPeter Garcia(Chief Financial Officer)SRSujata Rao(Chief Medical Officer)inSRStefan Ries(Chief Scientific Officer and Head of Munich Site)inAGAndrea Goddard(Chief Technical Officer)in

Co-investorsJEJeito CapitalBIBioqube VenturesFOForbionBABayern KapitalBIBioGeneration VenturesCACanaan Partners+2 more

Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.

BiotechDigital HealthMedical DevicesSan Diego, US

Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)inVikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)

Co-investorsFOForesite CapitalLOLongwood FundNONorwest Venture PartnersPIPivotal Life SciencesRIRiverVest Venture PartnersYSYsios Capital+4 more

Kivu Bioscience develops antibody-drug conjugate (ADC) therapeutics in clinical development, advancing a pipeline of cancer treatments through strategic partnerships and collaborations.

BiotechDeep TechHealthtechMedical Devices

MTMohit Trikha(CEO)inSRSophia Randolph(Chief Medical Officer)in

Co-investorsBIBioGeneration VenturesBOBOMGIGimvHEHealthCapM M VenturesNONovo Holdings

Rondo Therapeutics is an immuno-oncology biopharmaceutical company developing bispecific/multispecific antibody therapeutics designed for tumor-selective targeting to treat solid tumors while sparing healthy tissue.

BiotechHealthtech

SFShelley Force Aldred(Co-Founder & Chief Executive Officer)inNTNathan Trinklein(Co-Founder, President & CSO)inKatherine(Chief Development Officer)Thomas(Chief Medical Officer)

Co-investorsCACanaan PartnersDEDementia Discovery FundSVSV Health InvestorsJOJohnson & Johnson Innovation – JJDCNONovo Holdings

RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease.

BiotechHealthtech

Co-investorsFRFrazier Life SciencesLILifeArc VenturesOXOxford Science EnterprisesWEWellington ManagementEQEQT Life SciencesFOForbion+1 more

SynOx Therapeutics develops emactuzumab, a monoclonal antibody treatment for tenosynovial giant cell tumours (TGCT) and macrophage-mediated diseases.

BiotechHealthtechMedical Devices

RBRay Barlow(Chief Executive Officer)in

Co-investorsHEHealthCapBIBioqube VenturesFOForbionGIGimvMEMedicxi